Content area
Full Text
An 83-year-old woman developed nausea and dizziness after receiving potassium iodide for prophylaxis prior to 212PbTCMC-trastuzumab treatment for ovarian cancer; she subsequently experienced an allergic reaction following treatment with spironolactone for renal protection [routes and durations of treatments to reaction onsets not stated]. The evening prior to receiving 212Pb-TCMC-trastuzumab, the woman was administered a saturated solution of potassium iodide [dosage not stated] for 3 days as a precautionary measure; she developed nausea and dizziness (grade 1) [outcome not stated]. Spironolactone 100mg daily was started 10 days after trastuzumab administration for 6 months as a renal protective agent. An allergic reaction ensued necessitating withdrawal of spironolactone with subsequent resolution.